Video

Association Between BMI and Pancreatic Cancer Mortality

Eric J. Jacobs, PhD, cancer epidemiologist and strategic director of pharmacoepidemiology, American Cancer Society, discusses results from a prospective cohort study examining the association between BMI and pancreatic cancer mortality.

Eric J. Jacobs, PhD, cancer epidemiologist and strategic director of pharmacoepidemiology, American Cancer Society, discusses results from a prospective cohort study examining the association between BMI and pancreatic cancer mortality.

Those included in the research did not have cancer prior to the start of the study, says Jacobs, which enrolled 967,317 US adults between the ages of 30 and 89 years at enrollment. Results from the trial were presented at the 2019 AACR Annual Meeting and showed that excess body weight, at any age, was associated with increased risk of fatal pancreatic cancer. However, it is important to note that the increase in risk for weight measured in someone’s 30s or 40s was substantially larger than it was in someone who was measured in their 70s or 80s, says Jacobs.

Investigators found that in those who reported their weight when they were in their 30s or 40s, for every 5 units of BMI (about 30 or 35 pounds), there was a 25% increase in risk of pancreatic mortality for the rest of their lives going forward. When investigators looked at those between the ages of 70 and 80, they still saw increased risk, but it was only about half of that, demonstrating a clear trend. These findings mean that it matters when in life excess weight is measured, and excess weight in someone who is in their 30s or 40s could be incredibly important relative to weight gain later in life, concludes Jacobs.

<<< 2019 AACR Annual Meeting

Related Videos
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Tanios Bekaii-Saab, MD, FACP